Semax Research & Studies
Part of the full Semax guide - a synthetic melanocortin reference compound, identity-verified with a COA on every vial.
In brief
The research record cited for Semax is anchored by a tight cluster of primary studies from a single research lineage, principally Dolotov, Dmitrieva, Medvedeva and colleagues, working in rodent neurochemical and molecular-biology models. Rather than a broad clinical literature, the provided citations describe a focused mechanistic investigation: how a melanocortin-derived heptapeptide binds in brain membrane preparations and what it does to neurotrophin and receptor gene expression. Four peer-reviewed sources span 2006 to 2014, moving from receptor-binding characterization and ex-vivo BDNF/TrkB measurement toward transcriptional regulation in cerebral ischemia models, culminating in a genome-wide transcriptional analysis. This section summarizes what those specific sources actually investigated, the in-vitro and preclinical contexts they used, and the listed research areas they map onto, with every claim attributed only to the provided citations. No human, dosing, or therapeutic outcomes are described here; the framing throughout is receptor characterization and gene-expression analysis in rodent and ex-vivo systems.
The detail
A closer look
01
Receptor binding and the hippocampal BDNF/TrkB studies (2006)
Two 2006 papers by Dolotov and colleagues form the experimental core. The Journal of Neurochemistry study (PMID 16635254) characterized specific binding of Semax in rat basal forebrain, reporting the low-nanomolar KD (2.4 +/- 1.0 nM) and BMAX (33.5 +/- 7.9 fmol/mg protein) and documenting increased BDNF protein levels. The companion Brain Research study (PMID 16996037) examined the rat hippocampus, measuring BDNF and trkB expression after a single ex-vivo application: roughly 1.4-fold BDNF protein, about 1.6-fold TrkB tyrosine phosphorylation, approximately 3-fold exon III BDNF mRNA, and around 2-fold trkB mRNA. Together these map directly onto the listed research areas of BDNF/TrkB neurotrophin-receptor signaling in hippocampus and basal forebrain, and melanocortin/ACTH-fragment receptor-binding characterization, establishing both a binding site and a downstream neurotrophin response in ex-vivo and cell-model contexts.
02
Cerebral ischemia transcription and genome-wide analysis (2010-2014)
The later citations shift from acute signaling to gene transcription in injury models. Dmitrieva et al. (Cellular and Molecular Neurobiology 2010, PMID 19633950) reported that Semax and its Pro-Gly-Pro fragment activate transcription of neurotrophins and their receptor genes after cerebral ischemia, directly supporting the listed research area of neurotrophin and receptor gene transcription in cerebral ischemia models. Medvedeva et al. (BMC Genomics 2014, PMID 24661604) broadened the scope with a genome-wide transcriptional analysis in rat brain focal ischemia, examining the peptide's effect on genes related to the immune and vascular systems. This progression, from targeted neurotrophin readouts to whole-transcriptome profiling, characterizes how the cited literature investigated Semax's molecular footprint in preclinical ischemia models, again without any human or therapeutic claims attached to these provided sources.
03
Monoaminergic and stability research areas
The entry lists two further research areas that contextualize the peptide beyond the neurotrophin axis. First, monoaminergic modulation: rodent neurochemical assays are described as reporting modulation of dopaminergic and serotonergic systems, indicating that investigation of Semax extended to neurotransmitter-system readouts alongside neurotrophin signaling. Second, peptide enzymatic-stability and degradation kinetics in vitro, the line of work behind the structural rationale for the Pro-Gly-Pro tail. The provided data attributes the degradation characterization to a 2006 Amino Acids study, framing the C-terminal Pro-Gly-Pro as the element that shields the peptide from aminopeptidase cleavage. These two research areas round out the picture of what the cited and referenced work actually examined: binding affinity, neurotrophin and receptor transcription, monoamine modulation, and in-vitro metabolic stability, all in preclinical or cell-free systems.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Semax is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.